The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / T Cell Exhaustion: A New Strategy for Treating Autoimmune Disease

T Cell Exhaustion: A New Strategy for Treating Autoimmune Disease

July 27, 2015 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Science_Research_500x270New research suggests that T cell exhaustion appears to play an important role in the determination of autoimmune disease pathology. The investigation into the immunological transcription signature was conducted by Eoin F. McKinney, PhD, a research fellow at the University of Cambridge School of Clinical Medicine in the U.K., and colleagues. Their results were published online June 29 in Nature.

You Might Also Like
  • Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Gut Microbes Activate T Cells Causing Autoimmune Eye Disease
Also By This Author
  • GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes

“We show that the balance between co-stimulatory and co-inhibitory signals that shape T cell exhaustion coincides with opposite clinical outcomes during autoreactive and anti-viral immunity,” write the authors in their paper. “This at once allows prediction of outcome during infection and autoimmunity, and creates the potential for targeted therapeutic exhaustion of an autoimmune response in those predicted to follow an aggressive disease course. That this association is apparent in multiple autoimmune and inflammatory diseases emphasizes the importance of signals shaping T cell exhaustion in driving risk of relapse or recurrence (prognosis) rather than disease susceptibility (diagnosis) or immediate severity (disease activity), and suggests that targeted manipulation of these processes may lead to new treatment strategies that extend beyond the conditions discussed here.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators explain that a non-exhausted T cell is driven via CD2-induced co-stimulation. In contrast, T cells become exhausted via stimulation through the inhibitory receptor programmed cell death protein 1 (PD-1). The researchers have, thus, flagged PD-1 as a potential therapeutic target for the induction of exhaustion in T cells.

To further explore the plausibility of such a therapeutic approach, Dr. McKinney and colleagues identified a surrogate marker for the co-stimulation/exhaustion signature. They then examined patients to determine if there was an association between good clinical outcome and the signature. First, they looked at patients with chronic hepatitis C virus (HCV) infection. A combination of interferon and ribavirin therapy is associated with increased virus-specific T cell responses and consequent viral clearance in half of patients with chronic HCV infection who are treated with the therapeutic regimen. The investigators found that patients who responded best to the HCV therapy had the optimal stimulation/exhaustion signature. The same was true for individuals who were successfully vaccinated against infectious diseases.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We next asked whether surrogate detection of T cell co-stimulation/exhaustion modules could predict progression of other autoimmune diseases. Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by both autoantibodies and autoreactive CD4 T cells,” wrote the authors. They found that an unfavorable co-stimulation/exhaustion signature was associated with poor outcomes in patients with IPF, as well as other autoimmune and inflammatory diseases.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Autoimmune disease, Hepatitis C virus, T cell

You Might Also Like:
  • Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Gut Microbes Activate T Cells Causing Autoimmune Eye Disease
  • Abatacept Plus Prednisone Therapy Studied for Treating Giant Cell Arteritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.